-
中文名稱:小鼠成纖維細胞生長因子23(FGF23)酶聯(lián)免疫試劑盒
-
貨號:CSB-EL008629MO
-
規(guī)格:96T/48T
-
價格:¥3600/¥2500
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:小鼠成纖維細胞生長因子23(FGF23)酶聯(lián)免疫試劑盒(CSB-EL008629MO)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的FGF23含量。FGF23 是成纖維細胞生長因子 23,在調(diào)節(jié)磷和維生素 D 代謝中起關(guān)鍵作用。其異常表達與多種疾病相關(guān),如慢性腎臟病礦物質(zhì)和骨異常。研究機制主要聚焦于它與受體結(jié)合,調(diào)控下游信號通路,影響磷重吸收和維生素 D 活化。試劑盒檢測范圍為23.44 pg/mL-1500 pg/mL,適用于科研領(lǐng)域?qū)GF23蛋白水平的精確分析;為研究骨骼發(fā)育、礦物質(zhì)代謝紊亂、腎臟疾病等動物模型的分子機制提供可靠工具;滿足細胞實驗、疾病模型評估及藥物干預研究等科研需求;支持科研人員高效完成樣本中FGF23的定量檢測本品僅用于科研,不用于臨床診斷,產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
-
別名:Fgf23Fibroblast growth factor 23 ELISA kit; FGF-23 ELISA kit
-
縮寫:
-
Uniprot No.:
-
種屬:Mus musculus (Mouse)
-
樣本類型:serum, plasma, tissue homogenates
-
檢測范圍:23.44 pg/mL-1500 pg/mL
-
靈敏度:5.86 pg/mL
-
反應時間:1-5h
-
樣本體積:50-100ul
-
檢測波長:450 nm
-
研究領(lǐng)域:Signal Transduction
-
測定原理:quantitative
-
測定方法:Sandwich
-
精密度:
Intra-assay Precision (Precision within an assay): CV%<8% Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision (Precision between assays): CV%<10% Three samples of known concentration were tested in twenty assays to assess. -
線性度:
To assess the linearity of the assay, samples were spiked with high concentrations of mouse FGF23 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. Sample Serum(n=4) 1:1 Average % 102 Range % 98-107 1:2 Average % 85 Range % 80-90 1:4 Average % 91 Range % 85-95 1:8 Average % 94 Range % 90-98 -
回收率:
The recovery of mouse FGF23 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. Sample Type Average % Recovery Range Serum (n=5) 90 85-94 EDTA plasma (n=4) 97 93-101 -
標準曲線:
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. pg/ml OD1 OD2 Average Corrected 1500 2.614 2.468 2.541 2.386 750 2.103 2.095 2.099 1.944 375 1.587 1.513 1.550 1.395 187.5 1.002 1.074 1.038 0.883 93.75 0.564 0.554 0.559 0.404 46.88 0.356 0.382 0.369 0.214 23.44 0.245 0.239 0.242 0.087 0 0.159 0.151 0.155 -
數(shù)據(jù)處理:
-
貨期:3-5 working days
引用文獻
- High phosphate impairs arterial endothelial function through AMPK‐related pathways in mouse resistance arteries Weipeng Hu,Acta Physiologica,2020
- Microvasculopathy and soft tissue calcification in mice are governed by fetuin-A, magnesium and pyrophosphate Babler A,PLoS One,2020
- Soft tissue calcification in mice is governed by fetuin-A, pyrophosphate and magnesium Anne Babler, et al,Biorxiv,2019
相關(guān)產(chǎn)品
靶點詳情
-
功能:Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblasts differentiation and matrix mineralization. Upregulates EGR1 expression in the presence of KL.
-
基因功能參考文獻:
- Increases in plasma erythropoietin and erythropoietin receptor activation are mechanisms implicated in the increase of plasma FGF23 in acute kidney injury. PMID: 29395333
- our data highlight a role of FGF23/FGFR4 signaling in the regulation of cardiac remodeling and function, and indicate that pharmacological interference with cardiac FGF23/FGFR4 signaling might protect from CKD- and age-related LVH. PMID: 28512310
- the main physiological function of Klotho for mineral homeostasis in vivo is its role as co-receptor mediating Fgf23 action. PMID: 28600880
- our study provided histological evidences that sclerostin tends to be secreted in osteocytes of remodeled mature bone, while FGF23 would be differently synthesized in osteoblasts and osteocytes according to the developmental stages PMID: 28794403
- these results indicate that Nf1 deficiency in osteocytes dramatically increases FGF23 production and causes a mineralization defect (ie, hyperosteoidosis) via the alteration of calcium-phosphorus metabolism. PMID: 28425622
- FGF23 promotes myocardial fibrosis and exacerbates diastolic dysfunction induced by myocardial infarction or ischemia/reperfusion , which is associated with the upregulation of active beta-catenin and TGF-beta PMID: 27579618
- deleting FGF23 within early osteoblasts and osteocytes demonstrated that both cell types contribute to baseline circulating FGF23 concentrations, and that targeting osteoblasts/osteocytes for FGF23 production can modify systemic responses to changes in serum phosphate concentrations and rescue the Hyp genetic syndrome PMID: 26792657
- Thus, monotherapy with 1,25D improves growth, skeletal microarchitecture, and bone strength in the absence of phosphate supplementation despite enhancing FGF23 expression, demonstrating that 1,25D has direct beneficial effects on the skeleton in XLH, independent of its role in phosphate homeostasis PMID: 26751835
- Zinc13407541 also inhibited FGF-23 signaling in isolated renal tubules ex vivo and partially reversed the hypophosphatemic effects of excess FGF-23 in a mouse model. These chemical probes provide a platform to develop lead compounds to treat disorders caused by excess FGF-23. PMID: 27879395
- FGF23 may be an important modulator of PTH signaling in bone and kidney. PMID: 27498418
- EPO dependent regulation pathway of FGF23 gene expression PMID: 29073196
- can directly stimulate hepatic secretion of inflammatory cytokines PMID: 27457912
- Klotho in bone is crucial for inducing FGF23 production upon renal failure PMID: 28183805
- dietary iron content and chronic kidney disease affected FGF23 production and metabolism PMID: 27733366
- Dmp1 mutation creates a lower set point for extracellular phosphate and maintains it through the regulation of Fgf23 cleavage and expression PMID: 28005411
- Although FGF23 is present in the fetal circulation at levels that may equal adult values, and there is robust expression of FGF23 target genes in placenta and fetal kidneys, FGF23 itself is not an important regulator of fetal phosphorous metabolism. PMID: 27929669
- Annexin A7 deficiency upregulates FGF23 plasma levels, an effect paralleled by increased corticosterone plasma levels, as well as decreased 1,25(OH)2 D3 and PTH plasma levels. PMID: 27871077
- FGF23 regulates osteopontin secretion indirectly by suppressing alkaline phosphatase transcription and phosphate production in osteoblastic cells, acting through FGF receptor-3 in a Klotho-independent manner PMID: 26235988
- AHSG is produced in bone, mainly in osteocytes and also show for the first time that its production is modulated by FGF23. PMID: 26476373
- Data suggest that Fgf23 level in serum is up-regulated by three forms of exercise (acute exercise, exhaustive exercise, and chronic exercise); however, only chronic exercise up-regulates FGF23 mRNA and protein expression in skeletal muscle. PMID: 27085781
- Data suggest that signal transduction via Fgf23/Fgfr1 and calcitriol/calcitriol receptor have opposite roles in innate immunity; Fgf23 suppresses arginase-1 expression in macrophages; calcitriol stimulates arginase-1 expression in macrophages. PMID: 26762170
- results link CYP24 activity to the pathophysiology of FGF23-dependent renal phosphate wasting states and implicate pharmacologic CYP24 inhibition as a therapeutic adjunct for their treatment. PMID: 26784541
- Although the molecular link between the cardiac lesion and circulating Fgf23 concentrations remains to be identified, our study has uncovered a novel heart-bone-kidney axis PMID: 25858796
- Akt/PKB/SGK-sensitive GSK3 inhibition participates in the regulation of FGF23 release, 1,25(OH)2D3 formation, and thus mineral metabolism, by controlling the activity of the sympathetic nervous system. PMID: 26527066
- our data demonstrate that the effect of FGF23 on Pi homeostasis is mediated, at least in part, by activation of egr-1. PMID: 26588476
- Activation of FGFR1 is essential for the high levels of FGF23 in acute and chronic experimental uremia. PMID: 26311115
- findings revealed that FGF23 neutralization effectively improves bone quality and osseointegration of titanium implants in CKD mice, suggesting FGF23 as a key factor of CKD related bone diseases. PMID: 25665715
- the FGF23 proximal promoter harbors cis elements that drive responsiveness to 1,25D and calcium, agents that induce FGF23 to curtail the pathologic consequences of their excess. PMID: 26148725
- ctivation of autocrine/paracrine FGF pathways is involved in the pathogenesis of Hyp through FGFR1-dependent regulation of FGF23 by both transcriptional and post-transcriptional mechanisms. PMID: 25089825
- Normalization of serum FGF23 levels by did not abrogate the aggravated cardiac hypertrophy observed in Klotho-deficient chronic kidney disease. PMID: 25475745
- Fgf23-deficient mice are profoundly deaf. They have moderate hearing loss above 20 kHz, consistent with mixed conductive and sensorineural pathology of both middle and inner ear origin. these mice demonstrate dysplastic bulla and ossicles. PMID: 25243481
- Increased levels of circulating FGF23 in pathological conditions such as Hyp mice exerts direct effects on the placenta and affects fetal vitamin D metabolism. PMID: 24470103
- The polycystic kidney produces FGF23 but is resistant to its action. PMID: 24402093
- Fgf23- and Klotho-deficient mice show renal Na+ wasting and are hypovolemic. PMID: 24797667
- The stabilized Fgf23-autosomal dominant hypophosphatemic rickets allele reversed the Galnt3-null phenotype and normalized total Fgf23, serum phosphorus, and bone Fgf23 mRNA. PMID: 25051439
- High levels of FGF23 contribute to cardiovascular dysfunction. PMID: 25053401
- phosphate levels contribute in part to the high OPN levels in Fgf23(-/-) mice PMID: 24038141
- Circulating FGF23 level is increased in early chronic kidney disease (CKD) and is expressed in the vascular media of sham-operated mice; its expression is decreased in early CKD. PMID: 23884339
- disturbed iron and oxygen metabolism in neonatal life may have important effects on skeletal function and structure through FGF23 activity on phosphate regulation. PMID: 23873717
- FGF-23 is unlikely to have major effects on cardiovascular structure and function. PMID: 24525546
- The presence of Klotho-independent FGF23 effects in a Klotho-expressing target organ represents a paradigm shift in the conceptualization of FGF23 endocrine action PMID: 24348262
- Failed to find support for FGF23-mediated catabolism of vitamin D metabolites in chronic kidney disease assessed by 24,25(OH)(2)D levels. PMID: 22739976
- FGF23 directly affects the differentiation of bone marrow stromal cells PMID: 24068282
- P2Y13 receptor regulates phosphate metabolism and FGF-23 secretion with effects on skeletal development PMID: 24487286
- Data (including data from mutant/transgenic mice) suggest that FGF23 is not an important regulator of fetal phosphorous metabolism; active delivery of phosphorus across the placenta does not require FGF23. PMID: 24601885
- a novel role for FGF-23 in erythrocyte production and differentiation and suggest that elevated FGF-23 levels contribute to the pathogenesis of anemia PMID: 24509850
- observed a 3- to 10-fold increase in CYP27B1 mRNA abundance in the lung, spleen, aorta and testis of FGF-23 null/1alpha-Luc mice PMID: 24019880
- FGF23, not alphaKlotho, is a calcium-conserving hormone in the kidney. PMID: 24434184
- regulation of skeletal Fgf23 expression by sympathetic activity is dependent on the circadian clock system and may shed light on new regulatory networks of FGF23 PMID: 24302726
- High FGF23 variability in dialysis patients is mainly associated with lower baseline serum phosphorus. PMID: 23635517
顯示更多
收起更多
-
亞細胞定位:Secreted.
-
蛋白家族:Heparin-binding growth factors family
-
組織特異性:Mainly expressed in the brain and thymus at low levels. In brain; preferentially expressed in the ventrolateral thalamic nucleus.
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
Human Transforming Growth factor β1,TGF-β1 ELISA kit
Detect Range: 23.5 pg/ml-1500 pg/ml
Sensitivity: 5.8 pg/ml
-
-
-
Mouse Tumor necrosis factor α,TNF-α ELISA Kit
Detect Range: 7.8 pg/ml-500 pg/ml
Sensitivity: 1.95 pg/ml
-
-
-
-